// App-Quantinova.ai

74 : Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era

Researchers

Presenter

  • Paolo Anderlini

Principal Investigators

  • Rima Saliba

  • Celina Ledesma

  • Michelle A Fanale

  • Yasuhiro Oki

  • Jorge E Romaguera

  • Sattva S. Neelapu

  • Anas Younes

  • Richard E. Champlin

  • Christina M Chancoco

  • Tamera R. Alexander

  • Amin M. Alousi

  • Chitra Hosing

  • Issa F. Khouri

  • Yago L. Nieto

  • Uday R. Popat

  • Elizabeth J. Shpall

Medical Centers

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Mucositis

  • Lymphomas

Biomarkers

  • Circulating tumor cells

  • Estrogen receptor alpha

Drug/Treatment

  • Adcetris

  • Gemcitabine

  • fludarabine tablet

  • Melphalan

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved